Zhao P.,Viral Hepatitis Research Laboratory |
Xu D.,Viral Hepatitis Research Laboratory |
Wang X.,Shanghai University |
Duan G.,Shanghai University |
Huang L.,Viral Hepatitis Research Laboratory
Journal of Medical Colleges of PLA | Year: 2010
Objective: To evaluate the efficacy of entecavir and adefovir dipivoxil on HBeAg-positive nucleos(t)ide-naive patients with chronic hepatitis B with the method of Meta analysis. Methods: We searched PUBMED, EMBASE, CNKI (China National Knowledge Infrastructure), the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews with reference to all data documented before May 2010. The dosage of entecavir and adefovir dipivoxil was 0.5 mg/d and 10 mg/d, respectively. Heterogeneity was examined by Chi-square test, the relative risk calculated and forest plot drawn. Rates of undetected serum HBV DNA, serum alanine aminotransferase (ALT) normalization, HBeAg clearance, HBeAg seroconversion and adverse effect occurrence were analyzed. Results: Six articles were included, which fit well in with this study. Meta analysis showed that the rate of undetected serum HBV DNA (P=0.000 2 at week 12, P=0.002 at week 48) and that of serum ALT normalization (P=0.04 at week 12, P=0.008 at week 48) in the entecavir group were higher than those in the adefovir dipivoxil group. However, no statistic significance existed between the two groups in the rate of HBeAg clearance (P=0.17) , the rate of HBeAg seroconversion (P=0.53) or the rate of adverse effect occurrence (P=0.92) at week 48. Conclusion: Entecavir was superior to adefovir dipivoxil in decreasing serum HBV DNA and normalizing serum ALT in the HBeAg-positive nucleos(t)ide-naive patients with chronic hepatitis B.
Zhao P.,Academy of Military Medical Science |
Zhao P.,Viral Hepatitis Research Laboratory |
Xu D.-P.,Viral Hepatitis Research Laboratory |
Li X.-D.,Viral Hepatitis Research Laboratory |
And 2 more authors.
Academic Journal of Second Military Medical University | Year: 2010
Objective: To compare the application of nucleotide drugs and the virology characteristics between patients with only N236T mutation and patients with N236T+A181T mutation in the HBV reverse transcriptase (rt) region. Methods: Sera of patients with only rtN236T mutation and patients with rtN236T+rtA181T mutation were obtained from patients with chronic hepatitis B. Then the levels of sero-HBsAg, HBV DNA and ALT were determined and the HBV genotypes were analyzed. The treatment history with nucleotide drugs was retrospectively reviewed. Results: The sero-HBsAg levels were not significantly different between only rtN236T mutation group and rtN236T+rtA181T mutation group (P = 0.9755), and significantly higher viral replication (P = 0.0014) and higher ALT level (P = 0.0032) were found in rtN236T+rtA181T mutation group. Moreover, compared to HBV B genotype, patients with HBV C genotype were prone to carry rtN236T+rtA181T mutation (40% vs 20.45%, P = 0.0235); also we noticed that a switch from lamivudine medication to adefovir medication was liable to induce the virus mutation. Conclusion: Nucleotide drug application in HBV patients with only rtN236T mutation and rtN236T+rtA181T mutation are concurrent (lamivudine switching to adefovir). However, the HBV genotype constituents and the serum virological characteristics are different between the two types of HBV patients.
Xu Z.,Viral Hepatitis Research Laboratory |
Liu Y.,Viral Hepatitis Research Laboratory |
Liu L.,Center for Clinical Laboratory |
Li X.,Viral Hepatitis Research Laboratory |
And 6 more authors.
PLoS ONE | Year: 2013
Background and Aims:Interferon-gamma induced protein 10 (IP-10) was suggested to be involved in liver injury in viral hepatitis. This study aimed to investigate the impact of the single nucleotide polymorphisms (SNP) G-201A (rs1439490) in IP-10 gene on disease progression of hepatitis B virus (HBV) infection.Methods:The -201 SNP in IP-10 promoter was genotyped from 577 patients with different illness categories and 275 health controls; In vitro IP-10 promoter activity was compared between haplotype GG and AA homozygotes using luciferase reporter system in HepG2 cells. In vivo expression of IP-10 was compared between patients with -201 AA genotype and GG genotype.Results:The detected frequency of G-201A SNP was 17.8%, 25.3%, 26.6%, and 13.8% for patients with acute hepatitis B (AHB), patients with mild chronic hepatitis B (CHB-M), patients with severe chronic hepatitis B (CHB-S), and health controls, respectively. In vitro IP-10 promoter-driven luciferase activity in pGL3-Enhancer-201A transfected HepG2 cells was 1.43-fold higher than that in pGL3-Enhancer-201G transfected HepG2 cells (P<0.01). In vivo IP-10 transcriptional expression of peripheral blood mononuclear cells was 1.38-fold higher in patients with -201 AA genotype than in patients with -201 GG genotype (P<0.01).Conclusion:G-201A in promoter region of IP-10 gene was associated with liver disease progression in patients with HBV infection through up-regulating IP-10 expression. © 2013 Xu et al.